Chimeric Antigen Receptor T-Cell Therapy Pipeline Outlook Report 2025: Key 180+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight's, "Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Pipeline Insight, 2025" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Chimeric Antigen Receptor T-Cell Therapy (CAR-T) pipeline landscape. It covers the Chimeric Antigen Receptor T-Cell Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chimeric Antigen Receptor T-Cell Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive Chimeric Antigen Receptor T-Cell Therapy Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Chimeric Antigen Receptor T-Cell Therapy Pipeline Outlook Report [https://www.delveinsight.com/sample-request/chimeric-antigen-receptor-t-cell-therapy-car-t-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Chimeric Antigen Receptor T-Cell Therapy Pipeline Report

* In July 2025, Janssen Research & Development LLC announced a study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.
* In July 2025, Adicet Therapeutics conducted a Phase 1/2 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor [CAR] V1 T Cell product Targeting CD70 - in patients with R/R ccRCC.
* In July 2025, AstraZeneca organized a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants with refractory Systemic Lupus Erythematosus.
* DelveInsight's Chimeric Antigen Receptor T-Cell Therapy pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Chimeric Antigen Receptor T-Cell Therapy treatment.
* The leading Chimeric Antigen Receptor T-Cell Therapy Companies such as Cartesian Therapeutics, Arcellx, Inc, Nexcella, Inc, Autolus Therapeutics, Sana Biotechnology, Orgenesis, CARsgen, TILT Biotherapeutics, Poseida Therapeutics, Precision BioSciences, Novartis, Kyverna Therapeutics, Cemacabtagene ansegedleucel, Hrain Biotechnology, UTC Therapeutics, Kiromic, Suzhou Fundamenta Therapeutics, Gracell Biotechnology, Innovent Biologics/Nanjing IASO Biotherapeutics, CellabMED, Umoja Biopharma, TC BioPharm, ElevateBio, Century Therapeutics and others.
* Promising Chimeric Antigen Receptor T-Cell Therapy Pipeline Therapies such as Glofitamab, Obinutuzumab, Tocilizumab, Pembrolizumab, C-CAR066, Mosunetuzumab, Polatuzumab , and others.

Discover how the Chimeric Antigen Receptor T-Cell Therapy treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Chimeric Antigen Receptor T-Cell Therapy Clinical Trials and Studies [https://www.delveinsight.com/sample-request/chimeric-antigen-receptor-t-cell-therapy-car-t-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chimeric Antigen Receptor T-Cell Therapy Emerging Drugs Profile

* Descartes-08: Cartesian Therapeutics

Descartes-08 is an mRNA-modified, autologous CAR T-cell product directed against B-Cell Maturation Antigen (BCMA) that utilizes a novel modality and mechanism of action for treating gMG and other autoimmune diseases. Descartes-08 differs from anti-B-cell agents, which do not address long-lived plasma cells, and differs from FcRn blockers or complement inhibitors, which attempt to intervene only after autoantibodies are produced and pathogenic mediators are amplified. Descartes-08 is intended to halt production of autoantibodies by targeting pathogenic long-lived plasma cells with the potential to survive for decades within the body. Currently, the drug is in the Phase II stage of its development for the treatment of Myasthenia gravis (gMG).

* CART-ddBCMA: Arcellx, Inc

CART-ddBCMA is a genetically modified cell therapy utilizing a novel synthetic binding domain that is computationally designed, highly stable, and engineered to reduce immunogenicity. CART-ddBCMA is a Phase I study of Arcellx's BCMA-specific CAR-modified T-cell therapy utilizing the company's novel BCMA-targeting binding domain for the treatment of patients with relapsed and refractory multiple myeloma. The Arcellx ddBCMA cell therapy has been granted Fast Track Designation and Orphan Drug Designation by the U.S. Food and Drug Administration. The Phase I study is currently enrolling patients. CART-ddBCMA was well tolerated and rapid, deep, and durable responses were observed at the first dose level of 100 million cells, with six of six evaluable patients responding per IMWG criteria. Currently, the drug is in the Phase II stage of its development for the treatment of Multiple myeloma.

* NXC-201: Nexcella, Inc

NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis. NXC-201 (formerly HBI0101) is the only "Single-Day CRS" CAR-T cell therapy that is uniquely suited to target AL Amyloidosis and other autoimmune diseases. It is being studied in a comprehensive clinical development program for the treatment of patients with relapsed/refractory AL amyloidosis, and expanding into other autoimmune indications. These trials build on a robust NXC-201 clinical dataset initiated in February 2021. NXC-201 has been awarded Orphan Drug Designation (ODD) by the FDA in both AL Amyloidosis and multiple myeloma, and awarded EU ODD by the EMA in AL Amyloidosis. Currently, the drug is in the Phase I/II stage of its development for the treatment of AL Amyloidosis and multiple myeloma.

* AUTO-8: Autolus Therapeutics

AUTO8 is the next-generation product candidate for multiple myeloma which comprises two independent CARs for the multiple myeloma targets, BCMA and CD19. The company have developed an optimized BCMA CAR which is designed for improved killing of target cell that express BCMA at low levels. This has been combined with fast off rate CD19 CAR from obe-cel the company believes that the design of AUTO8 has the potential to induce deep and durable responses and extend the durability of effect over other BCMA CARs currently in development. Currently, the drug is in the Phase I stage of its development for the treatment of multiple myeloma.

* SG299: Sana Biotechnology

SG299, is the first drug candidate from the fusogen platform, in generating CD19-directed CAR T cells with in vivo delivery. In 2023, look forward to initial clinical data for SC291, allogeneic CAR T cells for patients with B cell cancers; filing an IND for SC262, allogeneic CAR T cells for patients that have failed previous CAR T therapy and filing an IND for SG299, in vivo CAR delivery program for patients with B cell cancers. Currently, the drug is in the Preclinical stage of its development for the treatment of chronic lymphocytic leukemia

The Chimeric Antigen Receptor T-Cell Therapy pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Chimeric Antigen Receptor T-Cell Therapy with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chimeric Antigen Receptor T-Cell Therapy Treatment.
* Chimeric Antigen Receptor T-Cell Therapy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Chimeric Antigen Receptor T-Cell Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chimeric Antigen Receptor T-Cell Therapy market.

Get a detailed analysis of the latest innovations in the Chimeric Antigen Receptor T-Cell Therapy pipeline. Explore DelveInsight's expert-driven report today! @ Chimeric Antigen Receptor T-Cell Therapy Unmet Needs [https://www.delveinsight.com/sample-request/chimeric-antigen-receptor-t-cell-therapy-car-t-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chimeric Antigen Receptor T-Cell Therapy Companies

Cartesian Therapeutics, Arcellx, Inc, Nexcella, Inc, Autolus Therapeutics, Sana Biotechnology, Orgenesis, CARsgen, TILT Biotherapeutics, Poseida Therapeutics, Precision BioSciences, Novartis, Kyverna Therapeutics, Cemacabtagene ansegedleucel, Hrain Biotechnology, UTC Therapeutics, Kiromic, Suzhou Fundamenta Therapeutics, Gracell Biotechnology, Innovent Biologics/Nanjing IASO Biotherapeutics, CellabMED, Umoja Biopharma, TC BioPharm, ElevateBio, Century Therapeutics and others.

Chimeric Antigen Receptor T-Cell Therapy (CAR-T) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Chimeric Antigen Receptor T-Cell Therapy Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key Thyroid Cancer Developments @ Chimeric Antigen Receptor T-Cell Therapy Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/chimeric-antigen-receptor-t-cell-therapy-car-t-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Chimeric Antigen Receptor T-Cell Therapy Pipeline Report

* Coverage- Global
* Chimeric Antigen Receptor T-Cell Therapy Companies- Cartesian Therapeutics, Arcellx, Inc, Nexcella, Inc, Autolus Therapeutics, Sana Biotechnology, Orgenesis, CARsgen, TILT Biotherapeutics, Poseida Therapeutics, Precision BioSciences, Novartis, Kyverna Therapeutics, Cemacabtagene ansegedleucel, Hrain Biotechnology, UTC Therapeutics, Kiromic, Suzhou Fundamenta Therapeutics, Gracell Biotechnology, Innovent Biologics/Nanjing IASO Biotherapeutics, CellabMED, Umoja Biopharma, TC BioPharm, ElevateBio, Century Therapeutics and others.
* Chimeric Antigen Receptor T-Cell Therapy Pipeline Therapies- Glofitamab, Obinutuzumab, Tocilizumab, Pembrolizumab, C-CAR066, Mosunetuzumab, Polatuzumab , and others.
* Chimeric Antigen Receptor T-Cell Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Chimeric Antigen Receptor T-Cell Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Chimeric Antigen Receptor T-Cell Therapy drug development? Find out in DelveInsight's exclusive Pipeline Report-access it now! @ Chimeric Antigen Receptor T-Cell Therapy Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/chimeric-antigen-receptor-t-cell-therapy-car-t-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Chimeric Antigen Receptor T-Cell Therapy (CAR-T) : Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name: Company Name
* Mid Stage Products (Phase II)
* Descartes-08: Cartesian Therapeutics
* Early Stage Products (Phase I/II)
* NXC-201: Nexcella, Inc
* Preclinical and Discovery Stage Products
* SG299: Sana Biotechnology
* Drug profiles in the detailed report.....
* Inactive Products
* Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Key Companies
* Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Key Products
* Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Unmet Needs
* Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Market Drivers and Barriers
* Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Future Perspectives and Conclusion
* Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Analyst Views
* Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chimeric-antigen-receptor-tcell-therapy-pipeline-outlook-report-2025-key-180-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chimeric-antigen-receptor-t-cell-therapy-car-t-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.